Q-omics provides the consensus-scored CBX7 profile across patient tissues and cancer cell-line models. CBX7 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, CBX7 is differentially expressed in 16, with the highest sampling consensus in BLCA. Additionally, CBX7 RNA expression shows 25,883 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight SKCM, BLCA, and LUAD as cancer lineages where CBX7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CBX7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CBX7 survival associations across molecular data types. CBX7 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CBX7 RNA expression–survival associations across cancer types. High CBX7 expression shows favorable associations in SKCM, MESO, KIRC, ACC, BRCA and LUAD. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for CBX7 RNA expression.
This table summarizes CBX7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRP for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CBX7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CBX7 shows lower tumor expression in BLCA, KIRP, COAD, KICH, LUAD and THCA. The BLCA box plot shows higher CBX7 RNA expression in normal versus tumor tissue (log2 FC = −4.107, t-test p < 0.001).
This table shows molecular features associated with CBX7 in patient tissues and cancer cell lines. In patient samples, CBX7 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, CBX7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and UPPER_AERODIGESTIVE_TRACT.
